The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
On the last day of the public comment period for CMS’s Aduhelm coverage proposal, former pediatrician Alan Schooley, now living with early-onset Alzheimer’s, shares…
The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects…
Medicare coverage of Alzheimer’s drug Aduhelm may soon be dramatically limited. The CMS is asking for public comments before finalizing the decision. Last week,…
Medicare premiums are going up in price across the board thanks in part to the anticipated cost of covering Aduhelm — but that doesn’t…
Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…